(1.26%) 5 127.79 points
(1.18%) 38 676 points
(1.99%) 16 156 points
(0.33%) $78.37
(0.84%) $2.16
(-0.20%) $2 304.00
(0.03%) $26.70
(-0.62%) $959.30
(0.08%) $0.930
(-0.06%) $10.87
(0.06%) $0.797
(0.00%) $91.45
Live Chart Being Loaded With Signals
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19...
Stats | |
---|---|
Dagens volum | 73 397.00 |
Gjennomsnittsvolum | 453 742 |
Markedsverdi | 5.92M |
EPS | $0 ( 2024-03-29 ) |
Neste inntjeningsdato | ( $-0.540 ) 2024-05-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.530 |
ATR14 | $0.00600 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Springer Graig | Buy | 100 000 | Options |
2024-01-05 | Springer Graig | Buy | 25 000 | Options |
2024-01-05 | Sarnoff David | Buy | 25 000 | Options |
2024-01-05 | Pavell Jeff | Buy | 25 000 | Options |
2024-01-05 | Linsley Wayne | Buy | 25 000 | Options |
INSIDER POWER |
---|
100.00 |
Last 63 transactions |
Buy: 4 493 741 | Sell: 2 121 250 |
Volum Korrelasjon
Hoth Therapeutics Inc Korrelasjon
10 Mest positive korrelasjoner | |
---|---|
APOP | 0.925 |
CMLF | 0.887 |
RMRM | 0.88 |
EMBCV | 0.864 |
FEYE | 0.843 |
TDAC | 0.835 |
MAGS | 0.828 |
SVOK | 0.814 |
GAINL | 0.811 |
ISNS | 0.808 |
Visste du det?
Korrelasjon er en statistisk måling som beskriver forholdet mellom to variabler. Den varierer fra -1 til 1, hvor -1 indikerer en perfekt negativ korrelasjon (hvor en variabel øker, går den andre ned), 1 indikerer en perfekt positiv korrelasjon (hvor en variabel øker, går den andre også opp), og 0 indikerer ingen korrelasjon (det er ingen forhold mellom variablene).
Korrelasjon kan brukes til å analysere forholdet mellom to variabler, ikke bare aksjer. Det er vanligvis brukt innen områder som finans, økonomi, psykologi, og mer.
Hoth Therapeutics Inc Korrelasjon - Valuta/Råvare
Hoth Therapeutics Inc Økonomi
Annual | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2023 |
Omsetning: | $0 |
Bruttogevinst: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2022 |
Omsetning: | $0 |
Bruttogevinst: | $-66 834.00 (0.00 %) |
EPS: | $-9.75 |
FY | 2021 |
Omsetning: | $0.00 |
Bruttogevinst: | $0.00 (0.00 %) |
EPS: | $-28.95 |
Financial Reports:
No articles found.
Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
Om Live Signaler
Live Trading signaler pa denne siden er ment til å hjelpe deg i beslutningsprossessen for når du bør KJØPE eller SELGE NA. Signalene har opp mot 1-minutt forsinkelse; som med alle andre indikatorer og signaler, er det en viss sjanse for feil eller feilkalkuleringer.
Live signalene er kun veiledende, og getagraph.com tar ikke noen form for ansvar basert pa handlinger gjort på disse signalene som beskrevet i Terms of Use. Signalene er basert på en rekke indikatorer og påliteligheten vil variere sterke fra aksje til aksje.